Abstract: The invention relates to aqueous formulations containing (?)-(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl 4,4,4-trifluorobutane-1-sulfonate. Said formulations are suitable as infusion solutions or as concentrate for producing these infusion solutions.

Abstract: A sterile packaging system for use in the manufacture and sale of combination medical product preferably one that is attachable to an injection system to co-deliver at least two medicaments is disclosed where a tray grid comprises sterile receptacles that are removably connected, sealable and configured for use in an automated drug filling and assembly line.

Abstract: In a method and apparatus for magnetic resonance (MR) imaging, a magnetization of nuclear spins in a subject is prepared in multiple preparation modules of an acquisition sequence. MR signals are acquired with at least one imaging module of the sequence. Spoiler gradient fields are generated in the multiple preparation modules in order to affect a transverse magnetization of the spins. The spoiler gradient fields that are applied in at least two different preparation modules are spatially varied along different directions. Spoiler gradient moments of the spoiler gradient fields are selected so that, for at least one of three orthogonal spatial directions, a weighted sum of the spoiler gradient moments that are applied along this spatial direction satisfies a threshold condition.

Abstract: The present invention relates to an assembly kit for preparing of a pre-filled syringe and in particular to a method of preparing of such pre-filled syringe assemblies by means of an assembly kit, wherein the assembly kit comprises: a gripping means to be attached to a proximal end section of a cartridge which comprises an axially displaceable bung for sealing of an interior volume of the cartridge being pre-filled with an injectable medicinal product, a needle mount to be attached to a distal end section of the cartridge and providing a mount for a needle assembly to be coupled to the interior volume of the cartridge in a fluid-transferring way, a plunger rod connectable with the bung of the cartridge for applying distally directed thrust to the bung, wherein the cartridge is at least partially embedded in a protecting sleeve.

Abstract: The invention relates to a pharmaceutical composition comprising methyl (2R,3R)-2-{3-[amino(imino)methyl]benzyl}-3-{[4-(1-oxidopyridin-4-yl)benzoyl]amino}butanoate or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable acidic reacting compound or to an aqueous solution or dispersion of the composition as well as a process for the preparation of the same, methods of using such compositions to treat subjects suffering from conditions which can be ameliorated by the administration of an inhibitor of Factor Xa.

Abstract: The invention refers to a cartridge (100), such as an injection cartridge, and to a needle system (200) therefore. Further, the invention refers to a combination of such an injection cartridge and a needle system. More specifically, the invention refers to a closure system for an injection cartridge which allows attachment of a needle system to the cartridge.

Abstract: In a method to configure at least one partial range of a pulse sequence for operating a magnetic resonance device, the pulse sequence is composed of at least two different program units, and information and/or at least one parameter is exchanged between the individual program units by a computerized mediator unit.

Abstract: The invention relates to aqueous formulations containing (?)-(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl 4,4,4-trifluorobutane-1-sulfonate. Said formulations are suitable as infusion solutions or as concentrate for producing these infusion solutions.

Abstract: In a magnetic resonance system according to a measurement protocol defined in advance and comprising multiple acquisition parameters, wherein given a non-compliance with at least one limit value (which is automatically established before the beginning of a subject-specific measurement data acquisition)—in particular a SAR limit value and/or a magneto-stimulation limit value and/or a hardware limit value—by the measurement protocol, an adaptation of at least one acquisition parameter ensues using at least one (in particular user-defined) protocol-specific rule for compliance with the limit value, and the measurement data acquisition ensues automatically according to the adapted acquisition parameters.

Abstract: The present invention relates to an aqueous pharmaceutical formulation which comprises 4-[((4-carboxybutyl)-{2-[(4-phenethylbenzyl)oxy]phenethyl}amino)methyl]benzoic acid or a salt thereof. The present invention relates in particular to an aqueous pharmaceutical formulation which comprises 4-[((4-carboxybutyl)-{2-[(4-phenethylbenzyl)oxy]phenethyl}amino)methyl]benzoic acid and 2-amino-2-(hydroxymethyl)-1,3-propanediol (trometamol).

Abstract: In a method for image generation by magnetic resonance with suppression of a spectral component of the magnetic resonance signal during the signal acquisition, k-space is sampled in sub-sections, an excitation pulse for excitation of the spectral component to be suppressed is radiated at a point in time TI before acquisition of each sub-section of k-space, and different TI values are selected for the respective sub-sections.

Abstract: In a magnetic resonance method and apparatus for acquisition of measurement data from a subject, k-space to be scanned into an inner region and an outer region, and the inner region is divided into inner segments that differ in terms of their distance from a k-space center and the outer region is divided into outer segments that differ in terms of their distance from a k-space center. First k-space data are acquired for the inner region, wherein k-space lines of the inner region are divided into first groups such that k-space lines from different inner segments are associated in each of the first groups, and the first groups are successively scanned. Second k-space data are acquired for the outer region, wherein k-space lines of the outer region are divided into second groups such that k-space lines from different outer segments are associated in each of the second groups, and the second groups are successively scanned.

Abstract: In a magnetic resonance method and apparatus for acquisition of measurement data from a subject, k-space to be scanned into an inner region and an outer region, and the inner region is divided into inner segments that differ in terms of their distance from a k-space center and the outer region is divided into outer segments that differ in terms of their distance from a k-space center. First k-space data are acquired for the inner region, wherein k-space lines of the inner region are divided into first groups such that k-space lines from different inner segments are associated in each of the first groups, and the first groups are successively scanned. Second k-space data are acquired for the outer region, wherein k-space lines of the outer region are divided into second groups such that k-space lines from different outer segments are associated in each of the second groups, and the second groups are successively scanned.

Abstract: In a method for image generation by magnetic resonance with suppression of a spectral component of the magnetic resonance signal during the signal acquisition, k-space is sampled in sub-sections, an excitation pulse for excitation of the spectral component to be suppressed is radiated at a point in time TI before acquisition of each sub-section of k-space, and different TI values are selected for the respective sub-sections.

Abstract: In a method and apparatus for improving the vessel/tissue contrast in time-of-flight angiography with a magnetic resonance tomography measurement, a sequence of radiofrequency excitation pulses is generated that each have a flip angle and a temporal spacing in the sequence defined by a repetition time, gradient pulses are generated with gradient coils such that, using an analog-to-digital converter, the magnetic resonance response signals are sampled in the frequency domain (k-space) in a slice referred to as a k-matrix, the k-matrix is sampled such that the respective distances of the measuring points from the center of the k-matrix are continuously increased (or decreased), and the repetition time is varied during the sampling, and/or the flip angle is varied during the sampling.

Abstract: The invention relates to an aqueous pharmaceutical composition containing moxifloxacin and less than 10 ppb iron.

Abstract: In a method and apparatus for improving the vessel/tissue contrast in time-of-flight angiography with a magnetic resonance tomography measurement, a sequence of radiofrequency excitation pulses is generated that each have a flip angle and a temporal spacing in the sequence defined by a repetition time, gradient pulses are generated with gradient coils such that, using an analog-to-digital converter, the magnetic resonance response signals are sampled in the frequency domain (k-space) in a slice referred to as a k-matrix, the k-matrix is sampled such that the respective distances of the measuring points from the center of the k-matrix are continuously increased (or decreased), and the repetition time is varied during the sampling, and/or the flip angle is varied during the sampling.

Abstract: The present invention relates to an aqueous formulation comprising moxifloxacin hydrochloride and sodium chloride, to the formulation for use as a medicament and to the use of the formulation for preparing a medicament for preventing or treating bacterial infections in humans or animals.

Abstract: Method for the in situ formulation of a medicinal substance solution for parenteral administration, in which at least two metered part-streams are continuously combined with the aid of a mixer to an active ingredient-containing total volumetric flow, characterized in that the resulting medicinal substance solution is not in thermodynamic equilibrium, and in that the resulting total volumetric flow after mixing is 0.2 ml/h to 500 ml/h, preferably 5 ml/h to 500 ml/h, an apparatus for carrying out the method, and an active ingredient administration kit which contains the apparatus.